The Formulations Core (Core B) will provide preformulation, formulation development, and formulation assessment efforts in direct support of Projects 1, 2, 3, &4. Within the scope of this program Core B will develop a novel delivery system utilizing a pellet technology developed by Auritec Pharmaceuticals. This technology will be developed for the fusion inhibitor RC-101 and the non nucleoside reverse transcriptase inhibitor CSIC both individually and in combination. Each of these drug candidates has hurdles to overcome to develop them into drug products. RC-101 is a hydrophilic peptide drug candidate while CSIC is hydrophobic in nature. The use of the pellet technology allows for co-delivery of these two very dissimilar drug candidates in a single product. For delivery to the vagina the pellets are inserted into a vaginal ring device. This drug delivery system will provide sustained release of both drug candidates offering a coitally independent drug product. We anticipate initially developing a drug product which will consistently deliver drug over a period of one month. Within the core, preformulation data on each of the drug candidates will initially be developed. This data will be used to successfully formulate the drug candidates. The pellet formulation effort will occur at Auritec Pharmaceuticals and the vaginal rings will be developed by Dr. Patrick Kiser at the University of Utah. Dr. Kiser additionally has the needed technology available to him to manufacture vaginal rings of appropriate size for use in macaque studies which will be necessary for successful completion of studies planned within this program. Preformulation assessments as well as pharmaceutical product assessments will be conducted by Dr. Lisa Rohan at the University of Pittsburgh. She will also coordinate the efforts of the three groups toward drug delivery system design and development. In addition within her group a secondary drug delivery platform (quick dissolve film) will be developed for these agents. The core will interact with Projects 1, 2, and 3 on an iterative basis throughout the drug product development stages and will ultimately provide drug product for use in macaque safety and efficacy studies being conducted in Project 4.

Public Health Relevance

The formulation core will develop a unique delivery platform for RC-101 and CSIC. This delivery system will consist of pelletized drug which maintains a sustained drug release profile over an extended time period. These efforts will lead to development of a safe and effective long lasting vaginal microbicide product which delivers two drug candidates simultaneously with different mechanisms of action against the HIV virus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082623-04
Application #
8380866
Study Section
Special Emphasis Panel (ZAI1-BP-A)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$182,619
Indirect Cost
$33,901
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Eade, Colleen R; Diaz, Camila; Chen, Sixue et al. (2015) HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria. Protein Pept Lett 22:672-80
Wood, Matthew P; Cole, Amy L; Eade, Colleen R et al. (2014) The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2. Immunology 142:474-83
Wood, Matthew P; Cole, Amy L; Ruchala, Piotr et al. (2013) A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. PLoS One 8:e55478
Eade, Colleen R; Cole, Amy L; Diaz, Camila et al. (2013) The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa. Am J Reprod Immunol 69:150-8
Eade, Colleen R; Diaz, Camila; Wood, Matthew P et al. (2012) Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS One 7:e50106
Levinson, Pauline; Choi, Robert Y; Cole, Amy L et al. (2012) HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. PLoS One 7:e31996
Eade, Colleen R; Wood, Matthew P; Cole, Alexander M (2012) Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Curr HIV Res 10:61-72
Penberthy, W Todd; Chari, Soumya; Cole, Amy L et al. (2011) Retrocyclins and their activity against HIV-1. Cell Mol Life Sci 68:2231-42
Rinehart, Matthew T; Drake, Tyler K; Robles, Francisco E et al. (2011) Time-resolved imaging refractometry of microbicidal films using quantitative phase microscopy. J Biomed Opt 16:120510
Micewicz, Ewa D; Cole, Amy L; Jung, Chun-Ling et al. (2010) Grifonin-1: a small HIV-1 entry inhibitor derived from the algal lectin, Griffithsin. PLoS One 5:e14360